Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV-MG01 in Moderate to Severe Myasthenia Gravis
NCT03165435Phase 3Withdrawn
- Sponsor
- CuraVac
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Peptides, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing CV-MG01 with Placebo (2 arms). Primary endpoint: Clinical efficacy at 24 weeks. Planned start Jul 2018; status: withdrawn.
02
Drugs
CV-MG01
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03165435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165435.